pPACK-SPIKE™ SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix

Safely study SARS-CoV-2 infectivity with pPACK-SPIKE, a system for generating high titers of SARS-CoV-2 “Spike” pseudotyped lentiviral particles.
  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 “S” protein in place of VSV-G envelope protein
  • Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
  • Compare to the widespread D614G Spike protein by using pPACK-SPIKE D614G
  • Start discovery and development with the mouse-adapted N501Y Spike protein by using pPACK-SPIKE N501Y

Products

Catalog Number Description Size Price Quantity Add to Cart
CVD19-500A-1 pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix 10 Reactions $702
- +
CVD19-510A-1 pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix (XL) 25 Reactions $1399
- +
CVD19-520A-KIT pPACK-SPIKE Combo Kit, includes Cat# CVD19-500A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) 1 Kit $1183
- +

Overview

Overview

Safely study SARS-CoV-2 interactions 

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 Spike glycoprotein. Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. In addition, you can compare this Spike protein from the original Wuhan-Hu-1 strain to the more prevalent (as of summer 2020) D614G Spike protein with pPACK-SPIKE D614G.

  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 “S” protein (the original Wuhan-Hu-1 strain) in place of VSV-G envelope protein
  • Efficiently incorporates the Spike protein into pseudoviral particles due to a 19 aa C-terminal truncation [1]
  • Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
  • Compare to the widespread D614G Spike protein by using pPACK-SPIKE D614G
  • Start discovery and development with the mouse-adapted N501Y Spike protein by using pPACK-SPIKE N501Y
pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all the available pPACK-SPIKE S protein variants:

Catalog NumberProduct DescriptionSPIKE PROTEIN MUTATION
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-590A-1pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-640A-1pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging MixL18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
CVD19-650A-1pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixT19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
CVD19-630A-1pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
CVD19-660A-1pPACK-SPIKE Omicron (B.1.1.529), SARS-CoV-2 "S" Pseudotype - Omicron (B.1.1.529) Variant - Lentivector Packaging MixA67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE

References

  1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.

References

How It Works

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.

Supporting Data

Supporting Data


Figure 1. pPACK-SPIKE pseudovirus particles efficiently infect ACE2 overexpression cells. pPACK-SPIKE packaging mix was used to generate Spike pseudoviral particles carrying a GFP-reporter vector, concentrated using PEG-it Concentration Reagent, and transduced ACE2-overexpressing cells. GFP imaging shows expression of the GFP reporter only in cells overexpressing ACE2, demonstrating the SARS-CoV-2-like behavior of the Spike pseudoviral particles. Data courtesy of Henry David Herce and Michelle Prew from Dana-Farber Cancer Institute and Harvard Medical School.

FAQs

Resources

Citations

Products

Catalog Number Description Size Price Quantity Add to Cart
CVD19-500A-1 pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix 10 Reactions $702
- +
CVD19-510A-1 pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix (XL) 25 Reactions $1399
- +
CVD19-520A-KIT pPACK-SPIKE Combo Kit, includes Cat# CVD19-500A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) 1 Kit $1183
- +

Overview

Overview

Safely study SARS-CoV-2 interactions 

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 Spike glycoprotein. Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. In addition, you can compare this Spike protein from the original Wuhan-Hu-1 strain to the more prevalent (as of summer 2020) D614G Spike protein with pPACK-SPIKE D614G.

  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 “S” protein (the original Wuhan-Hu-1 strain) in place of VSV-G envelope protein
  • Efficiently incorporates the Spike protein into pseudoviral particles due to a 19 aa C-terminal truncation [1]
  • Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
  • Compare to the widespread D614G Spike protein by using pPACK-SPIKE D614G
  • Start discovery and development with the mouse-adapted N501Y Spike protein by using pPACK-SPIKE N501Y
pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all the available pPACK-SPIKE S protein variants:

Catalog NumberProduct DescriptionSPIKE PROTEIN MUTATION
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-590A-1pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-640A-1pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging MixL18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
CVD19-650A-1pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixT19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
CVD19-630A-1pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
CVD19-660A-1pPACK-SPIKE Omicron (B.1.1.529), SARS-CoV-2 "S" Pseudotype - Omicron (B.1.1.529) Variant - Lentivector Packaging MixA67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE

References

  1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.

References

How It Works

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.

Supporting Data

Supporting Data


Figure 1. pPACK-SPIKE pseudovirus particles efficiently infect ACE2 overexpression cells. pPACK-SPIKE packaging mix was used to generate Spike pseudoviral particles carrying a GFP-reporter vector, concentrated using PEG-it Concentration Reagent, and transduced ACE2-overexpressing cells. GFP imaging shows expression of the GFP reporter only in cells overexpressing ACE2, demonstrating the SARS-CoV-2-like behavior of the Spike pseudoviral particles. Data courtesy of Henry David Herce and Michelle Prew from Dana-Farber Cancer Institute and Harvard Medical School.

FAQs

Citations